How to calculate the dose of chemotherapy - PubMed (original) (raw)

Case Reports

. 2002 Apr 22;86(8):1297-302.

doi: 10.1038/sj.bjc.6600139.

Affiliations

Free PMC article

Case Reports

How to calculate the dose of chemotherapy

Howard Gurney. Br J Cancer. 2002.

Free PMC article

Abstract

Body surface area-dosing does not account for the complex processes of cytotoxic drug elimination. This leads to an unpredictable variation in effect. Overdosing is easily recognised but it is possible that unrecognised underdosing is more common and may occur in 30% or more of patients receiving standard regimen. Those patients who are inadvertently underdosed are at risk of a significantly reduced anticancer effect. Using published data, it can be calculated that there is an almost 20% relative reduction in survival for women receiving adjuvant chemotherapy for breast cancer as a result of unrecognised underdosing. Similarly, the cure rate of cisplatin-based chemotherapy for advanced testicular cancer may be reduced by as much as 10%. The inaccuracy of body surface area-dosing is more than an inconvenience and it is important that methods for more accurate dose calculation are determined, based on the known drug elimination processes for cytotoxic chemotherapy. Twelve rules for dose calculation of chemotherapy are given that can be used as a guideline until better dose-calculation methods become available. Consideration should be given to using fixed dose guidelines independent of body surface area and based on drug elimination capability, both as a starting dose and for dose adjustment, which may have accuracy, safety and financial advantages.

Copyright 2002 Cancer Research UK

PubMed Disclaimer

Figures

Figure 1

Figure 1

Hypothetical phase I study of a drug with linear pharmacokinetics. Horizontal bars represent interpatient variation in systemic exposure. Each vertical tick mark represents an individual patient on the study. Dose level 3 would be considered the MTD and dose level 2 would be recommended for phase II study despite the majority of patients on that dose level having a systemic exposure in the sub-therapeutic range.

Comment in

Similar articles

Cited by

References

    1. AlexandreJBleuzenPBonneterreJSutherlandWMissetJLGuastallaJViensPFaivreSChahineASpielmanMBensmaineAMartyMMahjoubiMCvitkovicE2000Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients J Clin Oncol 18562573 - PubMed
    1. BerchJWiklundTEriksteinBLidbrinkELindmanHMalmstromPKellokumpu-LehtinenPBengtssonNOSoderlundGAnkerGWistEOttossonSSalminenELjungmanPHolteHNilssonJBlomqvistCWilkingN2000Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study Lancet 35613841391 - PubMed
    1. BishopJFDewarJTonerGCSmithJTattersallMHOlverINAcklandSKennedyIGoldsteinDGurneyHWalpoleELeviJStephensonJCanettaR1999Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front line therapy in untreated metastatic breast cancer J Clin Oncol 1723552364 - PubMed
    1. BudmanDRBerryDACirrincioneCTHendersonICWoodWCWeissRBFerreeCRMussHBGreenMRNortonLFreiIIIE1998Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B J Natl Cancer Inst 9012051211 - PubMed
    1. CarpenterJTMaddoxWALawsHLWirtschafterDDSoongSJ1982Favorable factors in the adjuvant therapy of breast cancer Cancer 501823 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources